MK-677 research and evidence overview

MK-677 research is unusually deep for a compound now sold on gray-market websites: it includes randomized dose-finding studies, a 2-year placebo-controlled trial in healthy older adults, a 563-patient Alzheimer's trial, and a phase IIb hip-fracture trial. The pattern across all of it is consistent — MK-677 reliably raises growth hormone and IGF-1, and that hormonal success never converted into a clinical benefit large enough, or safe enough, to justify approval. Merck's development program wound down after the Alzheimer's trial read out negative and the hip-fracture trial was stopped for a heart-failure signal.

The foundation was laid in the mid-1990s. In a randomized, double-blind study of 32 healthy adults aged 64–81, once-daily oral MK-677 increased 24-hour GH concentrations dose-dependently — about +97% at 25 mg — and raised serum IGF-1 from 141 to 265 µg/L, into the normal range for young adults, while preserving GH's pulsatile secretion pattern (Chapman et al., JCEM 1996). A companion literature documented downstream physiology: improved sleep quality with a near-50% REM increase in older subjects (Copinschi et al., Neuroendocrinology 1997) and increased markers of bone formation and resorption in 187 elderly adults (Murphy et al., J Bone Miner Res 1999).

On the hormone endpoints, in short, MK-677 works — a claim very few research-chemical compounds can support with randomized human data.

• Diet-induced catabolism (1998, n=8): in healthy volunteers on caloric restriction, 25 mg daily for one week reversed nitrogen losses (mean balance +0.31 vs −1.48 g/day on placebo) — a clean proof-of-concept for protein-sparing, in a tiny short study (Murphy et al., JCEM 1998).

• Obesity (1998, n=24): eight weeks in obese men raised IGF-1 ~40% and increased fat-free mass, but total and visceral fat were unchanged and glucose tolerance was impaired (Svensson et al., JCEM 1998).

• Healthy aging (2008, n=65): the 2-year Nass trial restored GH/IGF-1 to young-adult levels and added ~1.1 kg fat-free mass at 12 months, without strength or function gains, and with increased fasting glucose and decreased insulin sensitivity (Nass et al., Ann Intern Med 2008).

• Alzheimer's disease (2008, n=563): twelve months of 25 mg daily produced a 72.9% IGF-1 increase and no significant difference on any cognitive or functional measure (CIBIC-plus, ADAS-Cog, ADCS-ADL, CDR-sob) (Sevigny et al., Neurology 2008).

• Hip-fracture recovery (2011, n=123): the phase IIb trial was terminated early over a congestive heart failure safety signal in a limited number of patients; functional outcomes were mostly unimproved and the authors called the safety profile unfavorable (Adunsky et al., Arch Gerontol Geriatr 2011).

Put the trials side by side and the business decision explains itself. The populations most likely to benefit from restored GH — the frail elderly — were the ones who showed the heart-failure signal. The population with the cleanest mechanistic rationale — Alzheimer's patients, where IGF-1 was hypothesized to aid amyloid clearance — showed target engagement and zero clinical effect. And in healthy older adults, a year of treatment bought about a kilogram of lean mass at the price of measurably worse glucose handling. No indication survived the risk–benefit test, and no company has since revived the molecule for approval. Its afterlife is regulatory, not clinical: FDA warning letters to sports-supplement vendors (FDA, 2023) and an explicit listing among prohibited growth hormone secretagogues on the WADA Prohibited List.

Three habits keep this evidence base in perspective. First, separate hormone endpoints from outcome endpoints — MK-677 papers prove the former and repeatedly fail the latter. Second, check the population: an anti-catabolic effect in 8 dieting volunteers over 7 days says little about a year of use in a healthy 30-year-old. Third, note that the strongest safety findings came from the longest and largest trials — the direction the evidence moved as it got better is itself information. For the compound overview and FAQ, see the MK-677 detail page; for what the trials showed on the benefit side, see MK-677 benefits.